Thermo Fisher Scientific, the world leader in serving science, will significantly expand local operations in Indonesia with the opening of its first official office. The inauguration of the new facility in Jakarta is scheduled for April, signifying a key milestone as the company transitions from its current representative office to a larger workspace.
"The company is committed to advancing Indonesia's thriving science and technology landscape and support its progression in key areas such as healthcare, clean energy, biopharma and food safety," said Sho-Wen Yeo, vice president and general manager of Southeast Asia & Taiwan for Thermo Fisher Scientific.
Over the past year, Thermo Fisher has taken significant steps to strengthen its presence in Indonesia, including the establishment of a legal entity in the country. This strategic move aims to enhance customer proximity and deepen relationships with Indonesian stakeholders. The establishment of the new office in Jakarta is set to nurture local talent and support scientific advancements within the community.
To lead its growth and operations in Indonesia, Thermo Fisher has appointed Devi Darmadi as the country general manager. In this role, Darmadi will spearhead strategic initiatives and go-to-market evolution, geared toward expanding the company's footprint in Indonesia.
Thermo Fisher has previously also forged a strong partnership with National Research and Innovation Agency of Indonesia (BRIN, Badan Riset dan Inovasi Nasional) to strengthen research infrastructure and capabilities in the country. By leveraging its expertise and extensive portfolio, Thermo Fisher has become a key partner in supporting BRIN's goal of improving competencies and capacities for Indonesian researchers.
On February 24, Thermo Fisher also organized two scientific forums in Jakarta, bringing together industry experts and professionals. The forums facilitated discussions on transforming healthcare and pushing boundaries in lab solutions. Sessions included demonstrations of solutions available in Indonesia and their impact on labs and healthcare. Thermo Fisher also presented its extensive range of comprehensive solutions in areas of molecular diagnostics, oncology, clinical diagnosis, molecular spectroscopy, microbiology, toxicology, and sample storage.
"Plans in Indonesia to transition to renewable energy, strengthen research infrastructure and elevate healthcare and biotech ecosystems are highly promising," said Yeo. "I have great confidence in our growth trajectory here, and I believe we will continue to cultivate meaningful partnerships, enabling our customers to make the world healthier, cleaner and safer."
Write comment (0 Comments)
Pharmascience, the largest Canadian-owned pharmaceutical company, announced a major $120 million sterile injectable manufacturing facility expansion at its Candiac site. Following this important milestone, the company is now proud to announce the expansion of its contract development and manufacturing organization (CDMO) services with the creation of a new business unit dedicated to injectable products.
This new business unit will help accelerate production and achieve Pharmascience's growth objectives by enabling the company to offer its R&D, formulation and manufacturing services to external pharmaceutical partners. It will focus more specifically on injectable products, with a mandate to offer CDMO services to biotech companies and those with complex injectable product development or manufacturing needs.
Pharmascience's ambition is to become a world leader in the sterile injectable CDMO segment and serve pharmaceutical companies with world class services to meet the needs of customers and patients worldwide.
"With a vision to continue our expansion while supporting local development and manufacturing, we see a tremendous opportunity to expand our services to meet the needs of a growing pharmaceutical client base, whose complex injectable product supply requirements can be met by the extraordinary expertise of the Pharmascience team. Creating our new CDMO business unit represents an excellent way to maximize the value of our research and development efforts and the value of every unit we produce at our Candiac plant," says Martin Arès, CEO of Pharmascience.
Alongside the creation of this new CDMO business unit, Pharmascience is pleased to welcome John Foy as General Manager, CDMO since February.
Mr. Foy is a seasoned leader with an MBA from the University of North Carolina and a mechanical engineering degree from Lehigh University in Pennsylvania and has spent the last 24 years working at CDMOs, specializing in complex biologics and pharmaceuticals. He also has in-depth knowledge of the U.S. market knowledge, strategic thinking and market development expertise. His extensive experience and proven leadership will undoubtedly be major assets in helping Pharmascience position its CDMO business unit as a world leader in the sterile injectable products segment.
Pharmascience is pleased with its team's progress on the Candiac expansion project since the announcement last October. By 2026, the company will invest over $120 million to expand its facilities and more than triple its capacity with new state-of-the-art equipment. This will enable the company to support more patients, with annual production rising to more than 20 million units. This expansion is already well underway and will also enable Pharmascience to compete with international players and broaden its client base with a new range of products and services.
Write comment (0 Comments)
Synthetic biology could underpin an industry worth up to $30 billion per year and create over 50,000 new jobs by 2040, according to a new report by Australia’s national science agency, Commonwealth Scientific and Industrial Research Organisation (CSIRO), and Main Sequence Ventures.
The Synthetic Biology National Progress Report is an update to the 2021 National Synthetic Biology Roadmap which originally found the field would deliver an annual revenue of $27 billion and 44,000 jobs by 2040.
New projections have seen this figure increase to $30 billion and 50,000 new jobs, and the report found Australian synthetic biology startups received over $363 million in capital investments over the past three years.
According to CSIRO’s Health and Biosecurity Futures lead, Greg Williams, Australia has continued to foster a strong synthetic biology research and development ecosystem, with $44.5 million in research grants distributed over the last three years.
Gabrielle Munzer, Partner at Main Sequence Ventures, said that venture capital investment into cutting edge synthetic biology applications promises to deliver transformative benefits across a range of sectors.
Write comment (0 Comments)
With investments of approximately one billion euros, Japan headquartered Daiichi Sankyo will expand its production and development site in Pfaffenhofen an der Ilm, north of Munich, into an international innovation centre.
At least 350 new jobs will be created by 2030, including numerous positions for top international researchers, process engineers and other specialists in sterile and biotechnology.
In addition to more production capacities in the area of cardiovascular diseases, new laboratories will be created, particularly for antibody drug conjugate (ADC) technology. In the future, novel cancer therapies against, among other things, breast, lung and stomach cancer will be developed and manufactured in Pfaffenhofen.
The Pfaffenhofen production site has stood for the highest quality standards for more than 60 years. The medicines produced at the factory are shipped to more than 50 countries worldwide. Pharmaceutical development is also already taking place at the site. In addition, Pfaffenhofen is one of Daiichi Sankyo's largest sites in the world for the production of clinical products.
One of the elements of the investment is the new building for Daiichi Sankyo's ADC, which is scheduled to be completed by the end of 2026.
In addition to the areas of production and research, the investments also strengthen quality assurance and logistics. Renewable energies will play an increasingly important role: the plant already relies on wind, water, biomass and solar energy, which it generates itself either with its own systems or in cooperation with local partners.
Write comment (0 Comments)
Amgen announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date.
"Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway, chairman and chief executive officer at Amgen. "As part of Amgen's global biomanufacturing network, Amgen Ohio will play an important role in helping us address serious disease around the world with our innovative biomedicines."
The nearly 300,000-square-foot facility will employ 400 full-time staff. It also features open workspaces to foster collaboration and has been designed to meet the highest environmental sustainability standards, in support of Amgen's commitment to achieve carbon neutrality for all operations by 2027.
"This new Ohio facility is a success story in advanced healthcare manufacturing and the Made-in-America supply chain we need to live and thrive," said Lt. Governor Jon Husted. "Winning this project for Ohio creates 400 high-paying jobs and a $40 million annual payroll, supporting families and further growing the Ohio economy."
Amgen is a strong supporter of the communities in which its staff members work and live. In partnership with Columbus State Community College, Amgen is hosting an inaugural 18-month manufacturing apprenticeship at the site. This program, designed for those new to the field or changing careers, offers a blend of classroom and practical training, aiming to expand opportunities for skilled individuals without the requirement for a formal bachelor's degree.
Write comment (0 Comments)